← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Sanford Burnham Prebys Medical Discovery Institute
La Jolla, CA
$1,250,993,655
Total funding
986
Grants
Funding over time
peak $122.7M · FY2006–25$200M$150M$100M$50M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,194,706,016 · 917
DOD$49,273,096 · 58
NSF$2,648,719 · 6
NASA$2,535,268 · 3
DOE$1,830,556 · 2
By mechanism
R01$614,086,721 · 326
P01$142,627,476 · 131
U54$102,773,807 · 62
P30$89,406,185 · 104
U01$66,427,525 · 15
—$56,287,639 · 69
Investigators at Sanford Burnham Prebys Medical Discovery Institute
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Largest grants
Burnham Center for Chemical Genomics$16,808,207
U54 · FY2010 · HG
Sanford-Burnham Center for Chemical Genomics$16,752,454
U54 · FY2011 · HG
Burnham Center for Chemical Genomics$16,172,661
U54 · FY2009 · HG
Burnham Center for Chemical Genomics$15,280,302
U54 · FY2008 · HG
Center Driven Project #1$9,110,055
U54 · FY2010 · HG
Center Driven Project #1$8,408,358
U54 · FY2009 · HG
Center Driven Project #1$7,990,899
U54 · FY2008 · HG
Sanford-Burnham Center for Chemical Genomics$7,500,000
U54 · FY2012 · HG
Characterization, optimization, and development of dual mGlu2/3 positive allosteric modulators for opioid use disorder$6,445,203
R01 · FY2022 · DA
SAN DIEGO CHEMICAL LIBRARY SCREENING CENTER(RMI)$6,375,675
U54 · FY2007 · HG
San Diego Chemical Library Screening Center(RMI)$6,012,382
U54 · FY2007 · HG
Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders$5,014,452
UH3 · FY2023 · DA
Reversing Immune Dysfunction for HIV-1 Eradication$5,001,807
UM1 · FY2021 · AI
Chemistry$4,516,698
U54 · FY2011 · HG
Preclinical studies for the development of selective mGlu2 positive allosteric modulators to treat substance use disorders$4,332,196
U01 · FY2019 · DA
Clinical development of an mGlu2 positive allosteric modulator to treat nicotine addiction$4,154,854
U01 · FY2021 · DA
Molecular pathobiology of soluble TREM2 in Alzheimer's disease.$4,147,115
RF1 · FY2017 · AG
Global innate immune responses to HIV-1 infection$4,132,294
P01 · FY2014 · AI
High Throughput Screening$4,119,234
U54 · FY2011 · HG
Cancer Center Support Grant$4,091,161
P30 · FY2010 · CA